Fwd: Terpenoids and breast cancer chemoprevention.

---------- Forwarded message ----------
From: HubMed - breast cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Terpenoids and breast cancer chemoprevention.
To: mesothelioma77@gmail.com


[1]Breast Cancer Res Treat. 2008 Jul 19;
Rabi T, Bishayee A

Cancer chemoprevention is defined as the use of natural or synthetic agents that reverse, suppress or arrest carcinogenic and/or malignant phenotype progression towards invasive cancer. Phytochemicals obtained from vegetables, fruits, spices, herbs and medicinal plants, such as terpenoids, carotenoids, flavanoids, phenolic compounds, and other groups of compounds have shown promise in suppressing experimental carcinogenesis in various organs. Recent studies have indicated that mechanisms underlying chemopreventive action may include combinations of anti-oxidant, anti-inflammatory, immune-enhancing, and anti-hormone effects. Further, modification of drug-metabolizing enzymes, and influences on cell cycling and differentiation, induction of apoptosis, and suppression of proliferation and angiogenesis that play a role in the initiation and secondary modification of neoplastic development, have also been under investigation as possible mechanisms. This review will highlight the biological effects of terpenoids as chemopreventive agents on breast epithelial carcinogenesis, and the utility of intermediate biomarkers as indicators of premalignancy. Selected breast chemoprevention trials are discussed with a focus on strategies for trial design, and clinical outcomes. Future directions in the field of chemoprevention are proposed based on recently acquired mechanistic insights into breast carcinogenesis.



___
Source: http://www.hubmed.org/display.cgi?uids=18636327
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Understanding the concept of chemotherapy-related nausea: the patient experience.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Understanding the concept of chemotherapy-related nausea: the patient experience.
To: mesothelioma77@gmail.com


[1]Eur J Cancer Care (Engl). 2008 Jul 7;
Molassiotis A, Stricker CT, Eaby B, Velders L, Coventry PA

The aim of this study was to explore the experience of chemotherapy-related nausea in patients with cancer. A qualitative study was carried out with 17 patients who had experienced nausea during their chemotherapy in the UK and USA. Nausea was described as distressing and complex symptom. Patients attempted to construct an understanding of nausea using cognitive processes such as analysing their experience of nausea and related symptoms, attributing causation to nausea and comparing their experiences not only to their own expectations, but also to others' symptom experiences. A number of concurrent and associated symptoms linked with nausea were identified. Preliminary evidence emerged for nausea as part of a cluster of symptoms. Anti-emetic medication, provider-directed management strategies and self-management strategies were used by patients to minimize the effects of nausea. Self-management techniques, such as dietary strategies, were rooted in participants' understanding of nausea and their beliefs about what caused nausea, and there was little evidence of guidance from professionals beyond advice about medication management. This study reveals some of the complexities behind chemotherapy-induced nausea, including a potential symptom cluster, and contributes towards a clearer understanding of this symptom and its effects on patients' lives.



___
Source: http://www.hubmed.org/display.cgi?uids=18637116
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: Staged or simultaneous resection of synchronous liver metastases from colorectal cancer - A systematic review.

---------- Forwarded message ----------
From: HubMed - cancer <rssfwd@rssfwd.com>
Date: Sat, Jul 19, 2008 at 9:37 PM
Subject: Staged or simultaneous resection of synchronous liver metastases from colorectal cancer - A systematic review.
To: mesothelioma77@gmail.com


[1]Colorectal Dis. 2008 Jul 11;
Hillingsø JG, Wille-Jørgensen P

Aim A systematic review of the literature was undertaken to estimate the differences in length of hospital stay, morbidity, mortality and long-term survival between staged and simultaneous resection of synchronous liver metastases in order to determine the level of evidence for recommendations of a treatment strategy. Methods A Pub-med search was undertaken for studies comparing patients with synchronous liver metastases, who either had a combined or staged resection of metastases. Twenty-six were considered and 16 were included based on Newcastle Ottawa Quality Assessment Scale. All studies were retrospective and had a general bias, because the staged procedure was significantly more often undertaken in patients with left-sided primary tumours and larger, more numerous and bi-lobar metastases. Analyses of primary outcomes were performed using the random effects model. Results Due to the heterogeneity of the observational studies no odds ratios were calculated. In eleven studies there were a tendency towards a shorter hospital stay in the synchronous resection group. Fourteen studies compared total perioperative morbidity and lower morbidity was observed in favour of a combined resection. Fifteen studies compared perioperative mortality, which seemed to be lower with the staged approach. Eleven studies compared five-year survival, which seemed to be similar in the two groups. Conclusion No randomized controlled trials were identified, so a meta-analysis was not performed. The evidence level is II to III with grade C recommendations. Synchronous resections can be undertaken in selected patients, provided that surgeons specialised in colorectal and hepatobiliary surgery are available.



___
Source: http://www.hubmed.org/display.cgi?uids=18637099
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 

Fwd: High Unmet Need Spurs European Lung Cancer Therapeutics Market (Centre Daily Times)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: High Unmet Need Spurs European Lung Cancer Therapeutics Market (Centre Daily Times)
To: mesothelioma77@gmail.com


Revenues in the European lung cancer therapeutics market are set to grow at an accelerated pace due to the anticipated launch of products currently in phase III of development and the recent introduction of targeted therapies. Pharmaceutical and biotech companies are investing significant amounts of money in R&D in this sector.

Mon, 21 Jul 2008 18:15:47 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11p9ng07o/*http%3A//www.centredaily.com/business/story/725197.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc

 

Fwd: Gene panel predicts lung cancer survival, study finds (PhysOrg)

---------- Forwarded message ----------
From: Yahoo! News Search Results for lung cancer <rssfwd@rssfwd.com>
Date: Mon, Jul 21, 2008 at 5:48 PM
Subject: Gene panel predicts lung cancer survival, study finds (PhysOrg)
To: mesothelioma77@gmail.com


Researchers from four leading cancer centers have confirmed that an analysis involving a panel of genes can be used to predict which lung cancer patients will have the worst survival. The finding could one day lead to a test that would help determine who needs more aggressive treatment. The study, the largest of its kind, appears online in Nature Medicine.

Mon, 21 Jul 2008 16:19:02 GMT

___
Source: http://us.rd.yahoo.com/dailynews/rss/search/lung+cancer/SIG=11d34eiku/*http%3A//www.physorg.com/news135860184.html
--
 Powered by [4]RssFwd, a service of [5]Blue Sky Factory, Inc